Clinical Trials Browser

Phase 1/2 × Interventional × Desmoid Tumors × Clear all

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT00287846 2016-08-30

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Phase 1/2 Completed

40 enrolled

Sarcoma

Desmoid Tumors